Expanding treatment of tobacco dependence

Current Psychiatry Reports

Volumn 7, Issue 5, 2005, Pages 344-351

  Harris, Debra S ^b   Anthenelli, Robert M ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; AMFEBUTAMONE; AMINE OXIDASE (FLAVIN CONTAINING); AMPHETAMINE; CLONIDINE; CLORGYLINE; CP 526,555; DOPAMINE RECEPTOR BLOCKING AGENT; ENDOCANNABINOID; GLUTAMATE RECEPTOR; HALOPERIDOL; MECAMYLAMINE; METHAMPHETAMINE; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; NORTRIPTYLINE; OLANZAPINE; PHENELZINE; RIMONABANT; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TOBACCO SMOKE; TOPIRAMATE; TRANYLCYPROMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARENICLINE; VIGABATRIN;

AEROSOL; ANHEDONIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEWING GUM; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONSTIPATION; CURRICULUM; DOPAMINERGIC ACTIVITY; DRUG BIOAVAILABILITY; DRUG DEPENDENCE; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERANCE; DYSPEPSIA; FLATULENCE; HUMAN; HYPERTENSIVE CRISIS; INHALER; INSOMNIA; LOZENGE; MAJOR DEPRESSION; MEDICAL EDUCATION; MEDICAL SCHOOL; MOTIVATION; NAUSEA; NICOTINE REPLACEMENT THERAPY; NONHUMAN; NURSING; REVIEW; RISK REDUCTION; SCHIZOPHRENIA; SIDE EFFECT; SMOKING CESSATION; SOMNOLENCE; TASTE DISORDER; TOBACCO DEPENDENCE; TRANSDERMAL PATCH; URINARY EXCRETION; VIVID DREAM; WITHDRAWAL SYNDROME;

EID: 28044431846     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-005-0034-3     Document Type: Review

References (65)

1. World Health Organization: The World Health Report 2002: Reducing risks, promoting healthy life. Geneva: World Health Organization; 2002:1-94.
2. Jarvik ME, Schneider NG: Nicotine. In Substance Abuse: A Comprehensive Textbook, Second Edition. Edited by Lowinson JH, Ruiz P, Millman RB. Baltimore: Lippincott, Williams & Wilkins; 1992.
3. Fiore MC, Bailey WC, Cohen SJ, et al.: Clinical Practice Guideline. Treating Tobacco Use and Dependence. Rockville, MD: US Department of Health and Human Services; 2000.
4. Gorin SS, Heck JE: Meta-analysis of the efficacy of tobacco counseling by health care providers. Cancer Epidemiol Biomarkers Prev 2004, 13:2012-2022.
5. Roche AM, Freeman T: Brief interventions: good in theory but weak in practice. Drug Alcohol Rev 2004, 23:11-18.
6. Tait RJ, Hulse GK: A systematic review of the effectiveness of brief interventions with substance using adolescents by type of drug. Drug Alcohol Rev 2003, 22:337-346.
7. Balfour DJ: The neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus. Nicotine Tob Res 2004, 6:899-912.
8. Shiffman S, Waters AJ: Negative affect and smoking lapses: a prospective analysis. J Consult Clin Psychol 2004, 72:192-201.
9. Dani JA: Overview of nicotinic receptors and their roles in the central nervous system. Biol Psychiatry 2001, 49:166-174.
10. Pontieri FE, Tanda G, Orzi F, et al.: Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996, 382:255-257.
11. Fagen ZM, Mansvelder HD, Keath JR, et al.: Short- and long-term modulation of synaptic inputs to brain reward areas by nicotine. Ann N Y Acad Sci 2003, 1003:185-195.
12. Kelley AE: Memory and addiction: shared neural circuitry and molecular mechanisms. Neuron 2004, 44:161-179.
13. George TP, O'Malley SS: Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci 2004, 25:42-48.
14. Hutchison KE, Rutter MC, Niaura R, et al.: Olanzapine attenuates cue-elicited craving for tobacco. Psychopharmacology (Berl) 2004, 175:407-413.
15. Mahler SV, de Wit H: Effects of haloperidol on reactions to smoking cues in humans. Behav Pharmacol 2005, 16:123-126.
16. Brauer LH, Cramblett MJ, Paxton DA, et al.: Haloperidol reduces smoking of both nicotine-containing and denicotinized cigarettes. Psychopharmacology (Berl) 2001, 159:31-37.
17. Caskey NH, Jarvik ME, Wirshing WC, et al.: Modulating tobacco smoking rates by dopaminergic stimulation and blockade. Nicotine Tob Res 2002, 4:259-266.
18. Hughes J, Stead L, Lancaster T: Antidepressants for smoking cessation. Cochrane Database Syst Rev 2004; CD000031.
19. Gourlay SG, Stead LF, Benowitz NL: Clonidine for smoking cessation. Cochrane Database Syst Rev 2004; CD000058.
20. Berlin I, Anthenelli RM: Monoamine oxidases and tobacco smoking. Intl J Neuropsychopharmacol 2001, 4:33-42.
21. Berlin I, Said S, Spreux-Varoquaux O, et al.: A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin Pharmacol Ther 1995, 58:444-452.
22. Fowler JS, Logan J, Wang GJ, et al.: Low monoamine oxidase B in peripheral organs in smokers. Proc Natl Acad Sci U S A 2003, 100:11600-11605.
23. Anthenelli RM: Recent advances in the treatment of tobacco dependence. Clin Neurosci Res 2005, In press.
24. Watkins SS, Koob GF, Markou A: Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res 2000, 2:19-37.
25. Rose JE, Behm FM, Ramsey C, et al,: Platelet monoamine oxidase, smoking cessation, and tobacco withdrawal symptoms. Nicotine Tob Res 2001, 3:383-390.
26. Anthenelli RM, Tipp J, Li TK, et al.: Platelet monoamine oxidase activity in subgroups of alcoholics and controls: results from the Collaborative Study on the Genetics of Alcoholism. Alcohol Clin Exp Res 1998, 22:598-604.
27. Houtsmuller EJ, Thornton JA, Stitzer ML: Effects of selegiline (L-deprenyl) during smoking and short-term abstinence. Psychopharmacology (Berl) 2002, 163:213-220.
28. George TP, Vessicchio JC, Termine A, et al.: A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry 2003, 53:136-143.
29. Biberman R, Neumann R, Katzir I, et al.: A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction 2003, 98:1403-1407.
30. Mahmood I: Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clin Pharmacokinet 1997, 33:91-102.
31. Barrett JS, DiSanto AR, Thomford PJ, et al.: Toxicokinetic evaluation of a selegiline transdermal system in the dog. Biopharm Drug Dispos 1997, 18:165-184.
32. Barrett JS, Szego P, Rohatagi S, et al.: Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males. Pharm Res 1996, 13:1535-1540.
33. Mansvelder HD, De Rover M, McGehee DS, et al.: Cholinergic modulation of dopaminergic reward areas: upstream and downstream targets of nicotine addiction. Eur J Pharmacol 2003, 480:117-123.
34. Dani JA, De Biasi M: Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 2001, 70:439-446.
35. Silagy C, Lancaster T, Stead L, et al.: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004; CD000146.
36. Foulds J, Burke M, Steinberg M, et al.: Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs 2004, 9:39-53.
37. Slemmer JE, Martin BF, Damaj MI: Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 2000, 295:321-327.
38. Rose JE, Behm FM: Extinguishing the rewarding value of smoke cues: pharmacological and behavioral treatments. Nicotine Tob Res 2004, 6:523-532.
39. Lundahl LH, Henningfield JE, Lukas SE: Mecamylamine blockade of both positive and negative effects of IV nicotine in human volunteers. Pharmacol Biochem Behav 2000, 66:637-643.
40. Eissenberg T, Griffiths RR, Stitzer ML: Mecamylamine does not precipitate withdrawal in cigarette smokers. Psychopharmacology 1996, 127:328-336.
41. Rose JE, Behm FM, Westman EC, et al.: Mecamylamine acutely increases human intravenous nicotine self-administration. Pharmacol Biochem Behav 2003, 76:307-313.
42. Pomerleau CS, Pomerleau OF, Majchrzak MJ: Mecamylamine pretreatment increases subsequent nicotine self-administration as indicated by changes in plasma nicotine level. Psychopharmacology (Berl) 1987, 91:391-393.
43. Nemeth-Coslett R, Henningfield JE, O'Keeffe MK, et al.: Effects of mecamylamine on human cigarette smoking and subjective ratings. Psychopharmacology (Berl) 1986, 88:420-425.
44. Newhouse PA, Potter A, Corwin J, et al.: Acute nicotinic blockade produces cognitive impairment in normal humans. Psychopharmacology (Berl) 1992, 108:480-484.
45. Rose JE, Behm FM, Westman EC, et al.: Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther 1994, 56:86-99.
46. Tapper AR, McKinney SL, Nashmi R, et al.: Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science 2004, 306:1029-1032.
47. Picciotto MR, Zoli M, Rimondini R, et al.: Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 1998, 391:173-177.
48. Coe JW, Brooks PR, Vetelino MG, et al.: Varenidine (CP-526, 555): A novel, potent, and selective nicotinic receptor partial agonist for the treatment of smoking cessation: Rationale, discovery, and mode of action. Poster presented at the SRNT meeting in Prague, March 21, 2005.
49. Oncken C, Watsky E, Reeves K, et al.: Smoking cessation with varenicline, a selective nicotinic receptor partial agonist: Results from a Phase 2 study. Poster presented at the SRNT meeting in Prague, March 21, 2005.
50. Cohen C, Bergis OE, Galli F, et al.: SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation. J Pharmacol Exp Ther 2003, 306:407-420.
51. Paterson NE, Froestl W, Markou A: Repeated administration of the GARAB receptor agonist CGP44532 decreased nicotine self-administration, and acute administration decreased cue-induced reinstatement of nicotine-seeking in rats. Neuropsychopharmacology 2005, 30:119-128.
52. Dewey SL, Brodie JD, Gerasimov M, et al.: A pharmacologic strategy for the treatment of nicotine addiction. Synapse 1999, 31:76-86.
53. Brodie JD, Figueroa E, Laska EM, et al.: Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse 2005, 55:122-125.
54. Schiffer WK, Gerasimov MR, Marsteller DA, et al.: Topiramate selectively attenuates nicotine-induced increases in monoamine release. Synapse 2001, 42:196-198.
55. Skradski S, White HS: Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia 2000, 41(Suppl 1):S45-S47.
56. Johnson BA: Topiramate-induced neuromodulation of cortico-mesolimbic dopamine function: a new vista for the treatment of comorbid alcohol and nicotine dependence? Addict Behav 2004, 29:1465-1479.
57. Rose JE, Brauer LH, Rehm FM, et al.: Psychopharmacological interactions between nicotine and ethanol. Nicotine Tob Res 2004, 6:133-144.
58. Diana MA, Marty A: Endocannabinoid-mediated short-term synaptic plasticity: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE). Br J Pharmacol 2004, 142:9-19.
59. Gonzalez S, Cascio MG, Fernandez-Ruiz J, et al.: Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res 2002, 954:73-81.
60. Balerio GN, Aso E, Berrendero F, et al.: Delta9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice. Eur J Neurosci 2004, 20:2737-2748.
61. Cohen C, Perrault G, Griebel G, et al.: Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB(1)) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology 2005, 30:145-155.
62. Cohen C, Perrault G, Voltz C, et al.: SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol 2002, 13:451-463.
63. Cota D, Marsicano G, Tschop M, et al.: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003, 112:423-431.
64. Ravinet TC, Arnone M, Delgorge C, et al.: Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003, 284:R345-R353.
65. Dale LC, Anthenelli RM: Rimonabant as an aid to smoking cessation in smokers motivated to quit: results from a U.S. multicenter study - STRATUS US Trial. Paper presented at the Annual Meeting of the American College of Cardiology, New Orleans, LA, 2004.